Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease

Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease

“…The academic team agreed a priori that monotherapy with levodopa, dopamine agonists, catechol-O-methyl transferase (COMT) inhibitors, monoamine oxidase B (MAOB) inhibitors and anticholinergics all have evidence of efficacy with motor symptoms, at the expense of side effects. 21–25 The evidence is mostly from short term studies so longer term efficacy and adverse effects are uncertain. There is no good evidence regarding the optimal time for treatment initiation or dosage increase.…”

Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease

“…The academic team agreed a priori that monotherapy with levodopa, dopamine agonists, catechol-O-methyl transferase (COMT) inhibitors, monoamine oxidase B (MAOB) inhibitors and anticholinergics all have evidence of efficacy with motor symptoms, at the expense of side effects. 21–25 The evidence is mostly from short term studies so longer term efficacy and adverse effects are uncertain. There is no good evidence regarding the optimal time for treatment initiation or dosage increase.…”

A Literature Summary on Parkinson Disease

“…Seven RCTs incorporating 1100 patients failed to show ant consistent difference between them, in terms of occurrence and severity of motor complications, scores of impairment and disability, or the occurrence of side effects. Like Baker et al [10] and Stowe et al [23] , Van Hilten et al [24] concluded that there was a role for the use of dopamine agonists in improving motor impairments in early PD, but only in those patients who could tolerate the drug. For this, although six RCTs were located with 850 patients, a metaanalysis was not possible as there were methodological problems and incomparable outcome indicators.…”

“…Van Hilten et al ' s fi rst systematic review [24] on the use of bromocriptine in early PD compared a bromocriptine/levodopa combined therapy to levodopa alone. Seven RCTs incorporating 1100 patients failed to show ant consistent difference between them, in terms of occurrence and severity of motor complications, scores of impairment and disability, or the occurrence of side effects.…”

Bromocriptine treatment at the end of lactation prevents hyperphagia, higher visceral fat and liver triglycerides in early‐weaned rats at adulthood

“…14 For years, BRO was primarily used in the treatment of Parkinson's disease. 15,16 However, some studies have demonstrated that BRO treatment (10 mg/kg of body mass) in adult rats with obesity induced by diet for 4-6 weeks prevents excessive body mass gain and improves comorbidities such as hyperglycaemia, hyperinsulinaemia, glucose intolerance, hypertension, hepatic steatosis and higher mitochondrial oxidative stress. 17,18 Thus, since 2009, BRO, formulated as a quickrelease tablet, was approved by the US Food and Drug Administration (FDA) as a supporting therapy for non-insulin-dependent diabetes mellitus with poor glycaemic control when associated with dietetic control and physical activity.…”

“…For years, BRO was primarily used in the treatment of Parkinson's disease . However, some studies have demonstrated that BRO treatment (10 mg/kg of body mass) in adult rats with obesity induced by diet for 4‐6 weeks prevents excessive body mass gain and improves comorbidities such as hyperglycaemia, hyperinsulinaemia, glucose intolerance, hypertension, hepatic steatosis and higher mitochondrial oxidative stress .…”

Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease

“…The academic team agreed a priori that monotherapy with levodopa, dopamine agonists, catechol-O-methyl transferase (COMT) inhibitors, monoamine oxidase B (MAOB) inhibitors and anticholinergics all have evidence of efficacy with motor symptoms, at the expense of side effects. 21–25 The evidence is mostly from short term studies so longer term efficacy and adverse effects are uncertain. There is no good evidence regarding the optimal time for treatment initiation or dosage increase.…”

A Literature Summary on Parkinson Disease

“…Seven RCTs incorporating 1100 patients failed to show ant consistent difference between them, in terms of occurrence and severity of motor complications, scores of impairment and disability, or the occurrence of side effects. Like Baker et al [10] and Stowe et al [23] , Van Hilten et al [24] concluded that there was a role for the use of dopamine agonists in improving motor impairments in early PD, but only in those patients who could tolerate the drug. For this, although six RCTs were located with 850 patients, a metaanalysis was not possible as there were methodological problems and incomparable outcome indicators.…”

“…Van Hilten et al ' s fi rst systematic review [24] on the use of bromocriptine in early PD compared a bromocriptine/levodopa combined therapy to levodopa alone. Seven RCTs incorporating 1100 patients failed to show ant consistent difference between them, in terms of occurrence and severity of motor complications, scores of impairment and disability, or the occurrence of side effects.…”

Bromocriptine treatment at the end of lactation prevents hyperphagia, higher visceral fat and liver triglycerides in early‐weaned rats at adulthood

“…14 For years, BRO was primarily used in the treatment of Parkinson's disease. 15,16 However, some studies have demonstrated that BRO treatment (10 mg/kg of body mass) in adult rats with obesity induced by diet for 4-6 weeks prevents excessive body mass gain and improves comorbidities such as hyperglycaemia, hyperinsulinaemia, glucose intolerance, hypertension, hepatic steatosis and higher mitochondrial oxidative stress. 17,18 Thus, since 2009, BRO, formulated as a quickrelease tablet, was approved by the US Food and Drug Administration (FDA) as a supporting therapy for non-insulin-dependent diabetes mellitus with poor glycaemic control when associated with dietetic control and physical activity.…”

“…For years, BRO was primarily used in the treatment of Parkinson's disease . However, some studies have demonstrated that BRO treatment (10 mg/kg of body mass) in adult rats with obesity induced by diet for 4‐6 weeks prevents excessive body mass gain and improves comorbidities such as hyperglycaemia, hyperinsulinaemia, glucose intolerance, hypertension, hepatic steatosis and higher mitochondrial oxidative stress .…”

Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease

“…The academic team agreed a priori that monotherapy with levodopa, dopamine agonists, catechol-O-methyl transferase (COMT) inhibitors, monoamine oxidase B (MAOB) inhibitors and anticholinergics all have evidence of efficacy with motor symptoms, at the expense of side effects. 21–25 The evidence is mostly from short term studies so longer term efficacy and adverse effects are uncertain. There is no good evidence regarding the optimal time for treatment initiation or dosage increase.…”

A Literature Summary on Parkinson Disease

“…Seven RCTs incorporating 1100 patients failed to show ant consistent difference between them, in terms of occurrence and severity of motor complications, scores of impairment and disability, or the occurrence of side effects. Like Baker et al [10] and Stowe et al [23] , Van Hilten et al [24] concluded that there was a role for the use of dopamine agonists in improving motor impairments in early PD, but only in those patients who could tolerate the drug. For this, although six RCTs were located with 850 patients, a metaanalysis was not possible as there were methodological problems and incomparable outcome indicators.…”

“…Van Hilten et al ' s fi rst systematic review [24] on the use of bromocriptine in early PD compared a bromocriptine/levodopa combined therapy to levodopa alone. Seven RCTs incorporating 1100 patients failed to show ant consistent difference between them, in terms of occurrence and severity of motor complications, scores of impairment and disability, or the occurrence of side effects.…”

Bromocriptine treatment at the end of lactation prevents hyperphagia, higher visceral fat and liver triglycerides in early‐weaned rats at adulthood

“…14 For years, BRO was primarily used in the treatment of Parkinson's disease. 15,16 However, some studies have demonstrated that BRO treatment (10 mg/kg of body mass) in adult rats with obesity induced by diet for 4-6 weeks prevents excessive body mass gain and improves comorbidities such as hyperglycaemia, hyperinsulinaemia, glucose intolerance, hypertension, hepatic steatosis and higher mitochondrial oxidative stress. 17,18 Thus, since 2009, BRO, formulated as a quickrelease tablet, was approved by the US Food and Drug Administration (FDA) as a supporting therapy for non-insulin-dependent diabetes mellitus with poor glycaemic control when associated with dietetic control and physical activity.…”

“…For years, BRO was primarily used in the treatment of Parkinson's disease . However, some studies have demonstrated that BRO treatment (10 mg/kg of body mass) in adult rats with obesity induced by diet for 4‐6 weeks prevents excessive body mass gain and improves comorbidities such as hyperglycaemia, hyperinsulinaemia, glucose intolerance, hypertension, hepatic steatosis and higher mitochondrial oxidative stress .…”